Low-Dose Naltrexone: Month-by-Month Results for the First 3 Months
What counts as low-dose naltrexone?
Low-dose naltrexone, often shortened to LDN, uses the same medicine as standard-dose naltrexone in a smaller amount. Studies discussed below used daily doses from 1 mg to 6 mg, with several using 4.5 mg. These are study regimens, not instructions to select or increase a dose independently.
Standard 50 mg naltrexone tablets are approved for alcohol dependence and blocking the effects of externally administered opioids. LDN for the conditions in this article is off-label and is commonly prepared as a compounded capsule or liquid. Naltrexone does not prevent alcohol intoxication or function as an alcohol antidote. [1]
For an individual prescription, confirm the milligrams per capsule or the concentration of a liquid, the schedule and the intended treatment goal. The number of capsules or milliliters alone does not identify the dose.
Month 1: establish a baseline and track tolerability
Before looking for a treatment effect, choose the main outcome that matters to you. Examples include pain during an ordinary activity, the severity of fatigue, sleep quality or the ability to complete a routine task. Keep the same measure across the treatment period.
A brief weekly record can include:
- The dose actually taken and any changes directed by the prescriber.
- A rating for the main symptom using the same scale each time.
- One practical function measure, such as time spent on a usual household task.
- Sleep changes, nausea, headaches or other new symptoms.
- Other treatment changes, illness or unusual activity that week.
This is a suggested way to organize a follow-up discussion, not a validated LDN response calculator. It helps avoid mistaking one good or bad day for the overall result.
Vivid dreams and insomnia were reported as minor, transient effects in a 10-person fibromyalgia pilot. That study does not establish that everyone experiences them, or that they resolve within exactly one or two weeks. [2] Persistent sleep disruption deserves a discussion about the prescription rather than an assumption that it is evidence the medicine is working.
Similarly, worse energy or brain fog at the beginning should not automatically be described as an expected endorphin rebound. Record the change and discuss it with the prescriber. An unpleasant symptom is not proof of a future benefit.
Month 2: compare trends with the starting point
At five to eight weeks, use several observations rather than a single rating. Is the main symptom consistently better? Is everyday function improving too? Has a change lasted across more than one week?
An eight-week assessment has been used in MS research. A placebo-controlled crossover pilot enrolled 80 people, with 60 completing the trial, and evaluated 4.5 mg nightly. It found improvements in selected mental-health quality-of-life measures. Those results concern how participants felt and functioned on those measures; they do not show prevention of MS relapses or disability progression. [3]
A long COVID study used 1 mg in month one and 2 mg in month two. Of 52 participants, 38 were known to start treatment and 36 completed the follow-up questionnaire. Six of seven measured domains improved over two months. Because the study compared participants with their own starting results rather than a placebo group, it could not separate the medication's effect from recovery and other changes over time. [4]
These study endpoints are scheduled assessments. They do not mean that benefit must begin in week eight, that earlier improvement is impossible, or that everyone should increase to the same dose by then.
Month 3: review the result by condition
The three-month appointment should connect the original goal with the actual course of treatment. The following studies show why the condition and outcome matter.
| Condition and study | What was measured | Result relevant to a three-month discussion |
|---|---|---|
| Fibromyalgia, Younger and colleagues, 31 women | Daily pain with 4.5 mg versus placebo in a crossover trial | Pain fell 28.8% during LDN versus 18.0% during placebo; fatigue and sleep did not significantly improve [5] |
| Fibromyalgia, Due Bruun and colleagues, 99 women | Pain after 12 weeks of 6 mg versus placebo | Mean pain reduction was 1.3 points versus 0.9 points on a 0-10 scale; the between-group difference was not statistically significant [6] |
| Crohn's disease, Smith and colleagues, 40 adults | Disease activity and endoscopic findings after 12 weeks of 4.5 mg versus placebo | A reduction of at least 70 CDAI points occurred in 88% versus 40%; this was a response measure, not the same as remission [7] |
| MS, Cree and colleagues | Selected quality-of-life outcomes after eight weeks | Mental-health measures improved; the trial did not establish disease-modifying treatment effects [3] |
| Long COVID, O'Kelly and colleagues | Symptoms and daily-life effects after two months | Several domains improved in a study without a placebo comparison [4] |
For Crohn's disease, symptom improvement and control of intestinal inflammation are related but different goals. In the 12-week trial, endoscopic response occurred in 78% of the naltrexone group versus 28% of the placebo group. Treatment decisions should incorporate the gastroenterology team's disease assessments, not only a symptom diary. [7]
Why fibromyalgia results differ between studies
The 2013 crossover study is frequently cited because it found a greater pain reduction with 4.5 mg than with placebo. Its results should be considered alongside subsequent trials, rather than presented as the only controlled evidence. [5]
A 2023 crossover study randomized 58 people to 4.5 mg or placebo in approximately three-week treatment periods. It found no clinically relevant analgesic benefit on its primary measures. [8] In the separate 2024 study of 99 women, 12 weeks of 6 mg also did not outperform placebo for the primary pain outcome. [6]
A 2026 exploratory analysis revisited the same 99-person trial and examined response rates for tenderness, fatigue, sleep disturbance, depression, memory problems and stiffness. It found no significant differences between the treatment groups in those categories. This was an additional analysis of the original participants, not a new independent trial. [9]
For a patient, the practical point is to evaluate the actual response rather than assume that reaching a particular week or dose guarantees pain relief. A clear improvement can be discussed on its own merits; continued symptoms deserve an equally specific review.
Deciding whether to continue, adjust or stop
Bring the following to the three-month discussion:
| Pattern in your record | Useful question for the visit |
|---|---|
| Sustained symptom and function improvement | Is the benefit large enough to justify continuing the current plan? |
| Better symptom scores but unchanged daily function | Is the change meaningful for the goal we set? |
| Improvement followed by a plateau | Has the benefit persisted, and did anything else change? |
| No consistent improvement | Was the intended regimen followed, and is this the right treatment target? |
| Troublesome sleep or other adverse effects | Would changing the prescription or treatment approach improve the overall result? |
There is no universal requirement to remain on LDN for 12 weeks regardless of tolerability. There is also no established rule that Hashimoto's disease, lupus or psoriasis requires a longer trial simply because the condition is autoimmune. Those decisions need a condition-specific goal and a reason to continue.
Sleep, other medicines and liver monitoring
Some prescriptions use bedtime dosing. If sleep becomes worse, ask whether a timing or dose change fits the plan. A morning-versus-evening schedule has not been established by the trials summarized here as a way to guarantee better results.
Opioid medicines need specific review before starting naltrexone. It can block opioid pain relief and can precipitate withdrawal in someone who is physically dependent on opioids. Do not assume that a low dose removes that interaction. [1]
The current oral naltrexone label includes hepatotoxicity information in its warnings. Describing it as a current boxed warning is inaccurate. A smaller dose does not establish zero liver risk; the need for testing depends on liver history, other medicines and clinical findings. [1]
LDN studies are not head-to-head proof that it performs as well as duloxetine for fibromyalgia, or that it can replace established Crohn's or MS treatment. Keep other treatment decisions with the clinician managing that condition so that a change in one part of the plan can be interpreted correctly.
Frequently asked questions
How long does low-dose naltrexone take to work?
Do vivid dreams mean LDN is working?
Should I increase to 4.5 mg if I have no benefit?
Is three months always the minimum trial?
What should I bring to a three-month LDN appointment?
Does LDN prevent the effects of alcohol?
References
- DailyMed. Naltrexone hydrochloride tablets: prescribing information. Current label.
- Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Medicine. 2009. PubMed.
- Cree BAC, et al. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Annals of Neurology. 2010. PubMed.
- O'Kelly B, et al. Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study. Brain, Behavior, & Immunity - Health. 2022. PubMed.
- Younger J, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small randomized crossover trial. Arthritis & Rheumatism. 2013. PubMed.
- Due Bruun K, et al. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomized placebo-controlled trial. The Lancet Rheumatology. 2024. PubMed.
- Smith JP, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Digestive Diseases and Sciences. 2011. PubMed.
- Bested AC, et al. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized placebo-controlled crossover study. Pain Reports. 2023. PubMed.
- Symptom response to low-dose naltrexone in fibromyalgia: an exploratory analysis of the randomized placebo-controlled FINAL trial. 2026. PubMed.